Aurobindo Pharma Limited (AUROPHARMA.BO)
- Previous Close
1,103.55 - Open
1,111.80 - Bid --
- Ask --
- Day's Range
1,104.00 - 1,137.15 - 52 Week Range
581.50 - 1,177.00 - Volume
93,408 - Avg. Volume
112,362 - Market Cap (intraday)
662.785B - Beta (5Y Monthly) 0.58
- PE Ratio (TTM)
23.95 - EPS (TTM)
47.23 - Earnings Date May 25, 2024 - May 29, 2024
- Forward Dividend & Yield 4.50 (0.41%)
- Ex-Dividend Date Feb 20, 2024
- 1y Target Est
762.03
Aurobindo Pharma Limited engages in manufacturing of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, and internationally. It offers formulation in form of orals, injectables and over-the-counter drugs; and active pharmaceutical ingredients (API) for biosimilars, dermatology, respiratory, vaccines, and peptides, as well as oncology, hormones, and sterile products. The company also provides antiretroviral drugs for the people and children living with HIV; and AuroZymes, a biocatalysts product for use in the pharmaceutical and chemical industries. In addition, it offers AuroSource, a contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for penicillin's, cephalosporins, and non beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
www.aurobindo.com23,451
Full Time Employees
March 31
Fiscal Year Ends
Sector
Related News
Performance Overview: AUROPHARMA.BO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AUROPHARMA.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AUROPHARMA.BO
Valuation Measures
Market Cap
662.87B
Enterprise Value
654.99B
Trailing P/E
23.36
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.35
Price/Book (mrq)
2.29
Enterprise Value/Revenue
2.37
Enterprise Value/EBITDA
11.62
Financial Highlights
Profitability and Income Statement
Profit Margin
9.93%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
278.95B
Net Income Avi to Common (ttm)
27.7B
Diluted EPS (ttm)
47.23
Balance Sheet and Cash Flow
Total Cash (mrq)
71.49B
Total Debt/Equity (mrq)
23.58%
Levered Free Cash Flow (ttm)
--
Research Analysis: AUROPHARMA.BO
Company Insights: AUROPHARMA.BO
AUROPHARMA.BO does not have Company Insights